To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the highly selective oral p38alpha/beta mitogen-activated protein (MAP) kinase inhibitor Org 48,775-0 in a first-in-human study.
Proof of pharmacology of Org 48775-0, a p38 MAP kinase inhibitor, in healthy volunteers.
CHDR
Moerland M, Kales AJ, Broekhuizen K, Nässander U, Nelissen R, de Kam ML, Peeters PAM, Burggraaf J
